Felocell CVR-C (Canada)This page contains information on Felocell CVR-C for veterinary use.
The information provided typically includes the following:
- Felocell CVR-C Indications
- Warnings and cautions for Felocell CVR-C
- Direction and dosage information for Felocell CVR-C
Felocell Cvr-cThis treatment applies to the following species:
Feline Rhinotracheitis-calici-panleukopenia-chlamydia Psittaci Vaccine
Modified Live Virus and Chlamydia
For use in cats only
Product DescriptionFelocell CVR-C is for the vaccination of healthy cats as an aid in preventing feline viral rhinotracheitis (FVR) caused by feline herpesvirus-1, feline respiratory disease caused by feline calicivirus (FCV), feline panleukopenia (FPL) caused by feline parvovirus, and feline chlamydiosis caused by Chlamydia psittaci. Felocell CVR-C contains attenuated strains of feline rhinotracheitis virus, calicivirus, and panleukopenia virus (Johnson Snow Leopard strain), and C. psittaci, propagated on established cell lines. Felocell CVR-C is packaged in freeze-dried form with inert gas in place of a vacuum.
Disease DescriptionFVR, caused by feline herpesvirus-1, is highly contagious, spreading both by horizontal (including aerosol) and in utero transmission from queen to kitten. First signs of FVR are sneezing, fever, conjunctivitis, rhinitis, and salivation. An initial serous nasal and ocular discharge which rapidly becomes mucopurulent is typical of the disease. Ulcerative keratitis or glossitis may also occur. As FVR progresses, anorexia, depression, tracheitis, and bronchitis may be observed. Abortion or fetal resorption may occur. The prognosis is guarded if the cats remain severely infected for more than one week. A carrier state lasting for years with periods of latency alternating with episodes of viral shedding is common. Although few adult cats die from FVR, the death rate among affected kittens can range from 50% to 60%.
FCV infects oral mucous membranes as well as the respiratory tract. Buccal, nasal, and lingual ulcers are characteristic. Other clinical signs of the infection are similar to FVR: anorexia, depression, fever, salivation, and nasal discharge. A carrier state with persistent shedding occurs. FCV most severely affects kittens and debilitated cats, but overall death loss is generally low.
FPL, also known as feline distemper, was once one of the most widespread and serious diseases of cats but has been controlled by vaccination programs. Highly contagious, FPL is transmitted both directly by contact with infected animals and indirectly by contact with contaminated objects. Clinical signs of FPL include fever, anorexia, vomiting, depression, and weakness; diarrhea may also occur, usually two to four days after the onset of fever. Characteristic hematology includes a dramatic loss of circulating white cells. Particularly among kittens, FPL may result in high death loss. Cats that survive infection often remain debilitated for the remainder of their lives. Kittens infected in utero or within a few days after birth may suffer cerebellar damage clinically manifested by ataxia.
It is generally agreed that at least 90% of cases of upper respiratory disease are caused by feline herpesvirus-1 or feline calicivirus group. Numerous other agents such as Chlamydia, Mycoplasma, Bordetella, and reovirus have also been implicated in feline respiratory disease.
Chlamydia psittaci, an intracellular organism resembling a bacterium, replicates primarily in conjunctival and oronasal epithelium. It accounts for less than 5% of feline respiratory disease overall, although it may be a significant problem in catteries. The disease is typified by chronic conjunctivitis and mild rhinitis. Although the disease was once called “pneumonitis,” lower respiratory tract involvement does not appear to be significant. Early conjunctival signs of chlamydiosis usually are unilateral blepharospasm, congestion, and increased lacrimation, which may become bilateral and be accompanied by mucopurulent ocular discharge. Fever, rhinitis, and sneezing are infrequently observed. Anorexia and depression are uncommon. Some cats become carriers with intermittent shedding of organisms from the epithelium of the conjunctiva, gastrointestinal, and lower genital tracts. The course of infection is two to six weeks in kittens and up to two weeks in older cats, but the disease is rarely fatal.1-6
Safety EfficacySafety of Felocell CVR-C was demonstrated in laboratory tests and field trials involving 2,288 cats. The majority of the cats exhibited no serious post-vaccination reactions attributable to the vaccine. However, approximately 1% of the vaccinated cats exhibited lethargy, anorexia and fever following vaccination. (See Precaution 7.)
Efficacy of Felocell CVR-C was determined by challenge-of-immunity tests. Vaccinated cats experienced significantly less severe clinical signs than nonvaccinated control cats after challenge with virulent FVR virus, FCV, FPL virus, or C. psittaci.
Results of serological studies indicated that no immunologic interference existed among the vaccine fractions. In specific-pathogen-free cats, vaccination with Felocell CVR-C stimulated serologic titers to each of the four vaccine fractions.
1. General Directions: Vaccination of healthy cats is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well, and administer 1 mL intramuscularly or subcutaneously.
2. Primary Vaccination: Healthy cats 12 weeks of age or older should receive 2 doses, 3-4 weeks apart. Cats vaccinated at less than 12 weeks of age should be revaccinated at 12 weeks of age.
3. Revaccination: Annual revaccination with a single dose is recommended.
1. Store at 2°-7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.
2. Use entire contents when first opened.
3. Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals since traces of disinfectant may inactivate the vaccine.
4. Burn containers and all unused contents.
5. Contains gentamicin as preservative.
6. Vaccination of pregnant queens should be avoided.
7. The use of the product has been associated with fever, anorexia and lethargy in 1% of vaccinated cats, often occurring in clusters in association with multiple concurrent vaccinations. The onset is typically delayed for 7-21 days following vaccination. Symptoms may persist for 3-30 days with an average of 12 days after onset. Veterinary intervention may be required. When treatment is necessary, supportive care, steroids and antibiotics have been utilized.
8. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
9. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if the animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.
10. In case of accidental human exposure, consult a physician.
1. August JR: Feline viral respiratory disease. Vet Clin N Am: Sm Anim Pract 14:6:1159-1171, 1984.
2. Ford RB: Infectious respiratory disease. Vet Clin N Am: Sm Anim Pract 14:5:985-1006, 1984.
3. Ford RB: Viral upper respiratory infection in cats. The Compendium-Sm Anim 13:4:593-602, 1991.
4. Greene CE, ed: Infectious Diseases of the Dog and Cat, WB Saunders Com., pp. 346-357, 1990.
5. Pedersen NC: Feline Infectious Diseases, pp. 231-237, 1988.
6. Scott FW, ed: Infectious Diseases, Churchill Livingston, pp. 155-159, 1986.
7. Field trial data on file at Pfizer Animal Health.
Technical inquiries should be directed to Pfizer Animal Health Technical Services, (800) 366-5288 (USA), (800) 461-0917 (Canada).
For veterinary use only
U.S. Veterinary License No. 189
Pfizer Animal Health, Exton, PA 19341, USA, Div. of Pfizer Inc., NY, NY 10017
® Registered trademark of Pfizer Products Inc; Pfizer Canada Inc., licensee
PresentationAvailable in 25 x 1 dose.
Pfizer Canada Inc.
17300 TRANS-CANADA HIGHWAY, KIRKLAND, QC, H9J 2M5
|Technical Services Canada:||800-461-0917|
|Technical Services USA:||800-366-5288|
|Every effort has been made to ensure the accuracy of the Felocell CVR-C information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2014 North American Compendiums. Updated: 2014-09-05